Garner, Lucy C. http://orcid.org/0000-0002-6461-252X
Amini, Ali http://orcid.org/0000-0002-6837-8881
FitzPatrick, Michael E. B. http://orcid.org/0000-0003-2365-2012
Lett, Martin J. http://orcid.org/0000-0002-7230-9264
Hess, Gabriel F. http://orcid.org/0000-0001-8644-8292
Filipowicz Sinnreich, Magdalena
Provine, Nicholas M. http://orcid.org/0000-0002-9694-2216
Klenerman, Paul http://orcid.org/0000-0003-4307-9161
Funding for this research was provided by:
Wellcome Trust (109028/Z/15/Z, 216417/Z/19/Z, 222426/Z/21/Z)
Academy of Medical Sciences
Beyond Celiac - https://www.beyondceliac.org/about-beyond-celiac
UCB | UCB UK
Oxford-UCB Postdoctoral Fellowship - https://researchsupport.admin.ox.ac.uk/funding/ucb
U.S. Department of Health & Human Services | National Institutes of Health (U19 I082360)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PZ00P3_167828, PZ00P3_189490)
Uniscientia Stiftung
Goldschmidt-Jacobsen Stiftung - https://www.fundraiso.ch/sponsor/margot-und-erich-goldschmidt-peter-rene-jacobson-stiftung
Article History
Received: 11 January 2022
Accepted: 26 June 2023
First Online: 14 August 2023
Competing interests
: P.K. has acted as a consultant to UCB, Biomunex, AstraZeneca and Infinitopes. N.M.P. has acted as a consultant to Infinitopes. The other authors declare no competing interests.